Method of identifying natural antibodies for remyelination.
BACKGROUND
Natural autoantibodies are part of the normal human immunoglobulin repertoire. These antibodies react to self-antigens, are usually polyreactive with relatively low affinity, and typically are of the IgM isotype. Natural IgMs in mice that stimulated remyelination in central nervous system (CNS) demyelinating disease all shared the characteristics of binding to the surface of live oligodendrocytes and myelinated tracts in living slices of CNS tissue.


METHODS
A screen for human IgMs with similar character resulted in two human natural antibodies, which when injected peripherally into animal models of demyelination induced remyelination. A recombinant human IgM (rHIgM22) that also promoted remyelination in vivo was constructed.


RESULTS
Very small doses of this IgM are required for the promotion of remyelination (EC50 is 460 ng per 20-g mouse). It is clear that after peripheral delivery, rHIgM22 enters the CNS and accumulates in CNS lesions. rHIgM22 was tracked in living mice using ferritin-labeled antihuman mu chain antibodies visualized by magnetic resonance imaging and traditional immunocytochemistry. Although the exact antigen recognized by rHIgM22 is not known, all mouse IgMs that promote remyelination bind to myelin membrane lipids, suggesting the antigen for rHIgM22 is similar.


CONCLUSIONS
We propose that the IgMs bind to CNS cells and reorganize the membrane, initiating a signal that results in oligodendrocyte proliferation and/or protection with an end result of increased myelin. Recombinant natural human antibodies are potentially important therapeutic molecules that may modulate a wide spectrum of human disease.
Warrington
Arthur E
AE
Department of Neurology, Guggenheim 401, Mayo Clinic, Rochester, MN 55905, USA. warrington.arthur@mayo.edu
Rodriguez
Moses
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology*; D001812:Blood-Brain Barrier; D018188:Cardiovirus Infections / Q000276:immunology / Q000628:therapy* / Q000821:virology; D020278:Demyelinating Autoimmune Diseases, CNS / Q000276:immunology / Q000628:therapy* / Q000821:virology; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology* / Q000627:therapeutic use; D008563:Membrane Lipids / Q000276:immunology; D051379:Mice; D009103:Multiple Sclerosis; D009186:Myelin Sheath / Q000276:immunology / Q000502:physiology*; D009836:Oligodendroglia / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D012038:Regeneration; D013116:Spinal Cord / Q000276:immunology; D017945:Theilovirus
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007075:Immunoglobulin M; D008563:Membrane Lipids; D011993:Recombinant Fusion Proteins
J Neuroimmunol. 2004 Jan;146(1-2):153-61
14698858
Brain. 2000 Mar;123 Pt 3:519-31
10686175
Ann Neurol. 1990 Jan;27(1):12-7
2301922
J Neurosci Res. 2007 Apr;85(5):967-76
17304578
Curr Opin Immunol. 1995 Dec;7(6):812-8
8679125
Neurology. 1992 Feb;42(2):348-57
1736164
Prog Brain Res. 1992;91:149-54
1410399
J Neurosci. 1998 Oct 1;18(19):7700-8
9742140
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6820-5
10841576
Neurology. 2009 Apr 7;72(14):1269-76
19349608
J Neurosci. 1994 Oct;14(10):6230-8
7931575
FASEB J. 2004 Oct;18(13):1577-9
15319372
Mol Cell Neurosci. 2003 Jan;22(1):14-24
12595235
Neurobiol Dis. 2004 Feb;15(1):120-31
14751777
Crit Rev Immunol. 1987;7(4):325-65
2827957
Glia. 2002 Mar 1;37(3):241-9
11857682
FASEB J. 2002 Aug;16(10):1325-7
12154009
J Neurol Sci. 1997 Sep 10;150(2):103-13
9268236
Exp Neurol. 2007 Aug;206(2):248-56
17582399
J Neuropathol Exp Neurol. 1987 Jan;46(1):84-95
2432195
J Autoimmun. 2007 Dec;29(4):213-8
17888629
J Histochem Cytochem. 1996 Sep;44(9):1005-11
8773566